Sort by
Medicine and Dentistry
Uterine Cancer
100%
Pembrolizumab
52%
Sentinel Lymph Node
41%
Diseases
34%
Ovarian Cancer
33%
Robot-Assisted Surgery
32%
Progression Free Survival
27%
Immunotherapy
27%
Oncology
26%
Overall Survival
26%
Neoplasm
25%
Cervical Cancer
24%
Systematic Review
23%
Granulosa Cell Tumour
23%
Cancer
22%
Female Genital Tract Cancer
19%
Retroperitoneal Lymph Node Dissection
17%
Cytoreductive Surgery
17%
Meta-Analysis
17%
Recurrent Disease
17%
Minimally Invasive Procedure
15%
Endometrium Carcinoma
14%
Quality of Life
14%
Gynecological Oncology
14%
Body Mass Index
13%
Prospective Study
13%
Indocyanine Green
12%
Krukenberg Tumor
12%
Laparotomy
12%
Primary Peritoneal Cancer
12%
Fallopian Tube
12%
Microsatellite Instability
12%
Immunoglobulin
11%
Adenocarcinoma
11%
Surgeon
10%
Lymph Node
10%
Malignant Neoplasm
10%
Neoadjuvant Chemotherapy
10%
Biopsy Technique
9%
Sentinel Node
8%
Pelvis
8%
Hysterectomy
8%
Adverse Event
8%
Elderly Patient
8%
Health Care Cost
8%
Programmed Death-Ligand 1
8%
Immunotherapy Clinical Trial
7%
Rare Tumor
7%
Minimal Residual Disease
7%
Radioactive Tracer
7%
Keyphrases
Endometrial Cancer
79%
Pembrolizumab
54%
Sentinel Lymph Node Mapping
41%
Robotic Surgery
32%
Clinical Outcomes
28%
Ovarian Cancer
25%
Progression-free Survival
24%
Overall Survival
24%
Survival Outcomes
21%
Sentinel Lymph Node
19%
Confidence Interval
17%
Minimally Invasive Surgery
17%
Basket Trial
17%
Adult Granulosa Cell Tumor
16%
Gynecological Cancer
15%
Gynecologic Malignancies
14%
Recurrent Endometrial Cancer
14%
Tumor
14%
Detection Rate
14%
Microsatellite Instability-high (MSI-H)
13%
Gynecologic Oncology
13%
Robotics
13%
Cytoreductive Surgery
13%
Clinical Trials
12%
Primary Peritoneal Cancer
12%
Fallopian Tube
12%
Cervical Injection
11%
Ovarian Granulosa Cell Tumor
11%
Meta-analysis
11%
Immuno-oncology
11%
Endometrial Carcinoma
11%
Management Strategy
11%
Systematic Meta-analysis
11%
Locally Advanced Cervical Cancer
11%
Blue Dye
11%
Selinexor
11%
Adenocarcinoma
11%
Mesonephric-like
11%
Chemotherapy
11%
Partial Response
10%
Body Mass Index
10%
Operative
10%
Adverse Events
9%
Metastatic Melanoma
9%
PD-1 Blockade
9%
Cervical Cancer
9%
Epithelial Ovarian Cancer
9%
Health-related Quality of Life
9%
Multivariable
9%
Indocyanine Green
9%